H.R. 6625 · 117th Congress
Equal Access to Therapeutics Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
DavisSponsor16 cosponsors · 16 R
R
Bost
KC
R
Cammack
RF
R
Feenstra
SG
R
Graves
AG
R
Garbarino
DL
R
Lamborn
NM
R
Malliotakis
CT
R
Tenney
BV
R
Van Duyne
JF
R
Fortenberry
BG
R
Gibbs
DM
R
McKinley
JV
R
Van Drew
GG
R
Grothman
CJ
R
Jacobs
JS
R
Smith9 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies).
What it does: CRS summary · Introduced in House · Feb 7, 2022
Equal Access to Therapeutics Act
This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies).
Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance.
The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Equal Access to Therapeutics Act
Latest action (Feb 8, 2022): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Feb 7, 2022
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.